As Feds Probe Pharma’s Middlemen, Capital Rx Raises $106 Million For Software-Driven Fix
Thank you to Forbes’ Katie Jennings for expertly summarizing the challenges consumers face as a result of rising drug prices, as well as how Capital Rx’s $106M Series C funding will help accelerate the company's mission.
The Federal Trade Commission took aim at the prescription drug middlemen known as pharmacy benefit managers last week, announcing an inquiry into the opaque system of rebates, claw backs and other financial wizardry that determines how much patients end up paying at the pharmacy counter. The timing couldn’t be better for AJ Loiacono, the cofounder and CEO of Capital Rx, who has spent the past five years building price transparency and claims processing software for this moment. Read the Forbes article here.